Skip to main content

Published locations for The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis

User login

  • Reset your password
  • /content/case-anti-il-17-agents-first-line-biologics-psoriatic-arthritis
  • /edermatologynews/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line-biologics
  • /fedprac/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line-biologics-psoriatic
  • /rheumatologynews/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line-biologics
  • /rheumatology/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line-biologics
  • /dermatology/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line-biologics-psoriatic
  • /rheumatology/psoriatic-arthritis-resource-center/article/232580/psoriatic-arthritis/case-anti-il-17
  • /psoriatic-arthritis-icymi/article/232580/psoriatic-arthritis/case-anti-il-17-agents-first-line